Roche Has Eylea In Its Sights After Farcimab Approval
FDA Backs First Bispecific Antibody For The Eye
Executive Summary
Roche’s bispecific antibody, to be called Vabysmo, has got US approval for wet age-related macular degeneration and diabetic macular edema, markets where Bayer and Regeneron's Eylea is a huge seller. The Swiss company hopes that its less-frequent dosing advantage and a price that offers savings over time will make an impact on the market.
You may also be interested in...
Regeneron’s CRL For High-Dose Eylea Benefits Roche, Vabysmo
Although the US FDA complete response letter only cites third-party manufacturing issues, analysts say the delayed approval of 8mg Eylea could continue a competitive advantage for Vabysmo into 2024.
Roche’s Vabysmo Advantage Over Eylea Hard To See In Latest Head-To-Head
Roche’s next-generation eye drug Vabysmo has enjoyed a strong launch, but new head-to-head trials in a potential new indication, retinal vein occlusion, appear to offers up few advantages over market leader Eylea.
Five Clinical Trial Hits Of 2022
Any given year sees a variety of clinical trials produce positive or negative results. But some of those trials are especially important either for moving a field forward or for a company’s overall development and commercial strategy. Here, Scrip looks at some of the more notable trial successes of the last year.